Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Some general concepts (statin lowers lipids; muscle adverse effects/myopathy risk) loosely align with label sections provided, but many specific claims (exact incidence rates, timing variability, risk factors wording, management steps, hydration advice, and frequency wording) are not supported by the supplied excerpts and include potentially misleading specificity.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
SECTION 12.1 (mechanism: inhibits HMG-CoA reductase; cholesterol/triglycerides effects) and SECTION 1.2 (adjunct to diet to reduce total-C/LDL-C and TG; increase HDL-C).
Muscle weakness is a known side effect of Lipitor (atorvastatin).
SECTION 5.1 (skeletal muscle: myopathy/rhabdomyolysis risk) and SECTION 6 (adverse reactions include myopathy/rhabdomyolysis discussed in greater detail). Note: label excerpt does not explicitly use the phrase 'muscle weakness' but supports skeletal muscle toxicity.
Unsupported Statements
Lipitor is used to prevent heart disease.
Label excerpt supports prevention of cardiovascular disease/CHD outcomes (e.g., MI, stroke, revascularization, angina) but does not explicitly use wording 'prevent heart disease.' This is partially supported as prevention of cardiovascular events, but the claim is broader than the excerpt.
Muscle weakness is one of the most common side effects of statins, including Lipitor, according to the FDA.
Provided label excerpt lists common adverse reactions (e.g., myalgia 0.7%, arthralgia 6.9%, nasopharyngitis 8.3%) but does not identify 'muscle weakness' or state it is 'one of the most common side effects' or 'according to the FDA' for muscle weakness.
In a study, muscle weakness was reported by 12.3% of patients taking Lipitor.
No such incidence for 'muscle weakness' is present in provided label excerpts (SECTION 6.1 only provides specific incidences for certain adverse reactions; none correspond to this value or 'muscle weakness').
In the same study, muscle weakness was reported by 4.5% of patients taking placebo.
No such incidence for 'muscle weakness' is present in provided label excerpts.
Muscle weakness can occur in anyone who takes Lipitor.
Label excerpt describes rare cases of rhabdomyolysis and occasionally causes myopathy; it does not support the universal risk phrasing 'in anyone.'
Muscle weakness timing during Lipitor use can vary between people.
No timing statements regarding onset of muscle weakness/myopathy are included in the provided excerpts.
Some people may experience muscle weakness shortly after starting Lipitor.
No onset timing statements are included in the provided excerpts.
Some people may not notice muscle weakness symptoms until they have been taking Lipitor for several months.
No onset timing statements are included in the provided excerpts.
Certain factors can increase the risk of muscle weakness with Lipitor, including age.
Label excerpt supports advanced age (≥65) as a predisposing factor for myopathy and use with caution (SECTION 8.5), but does not specifically list 'age' as a factor for 'muscle weakness' nor support the general 'muscle weakness' risk phrasing.
Older adults may be more susceptible to muscle weakness when taking Lipitor due to decreased muscle mass and strength.
Label excerpt supports advanced age as a predisposing factor for myopathy (SECTION 8.5) but does not provide the mechanism 'decreased muscle mass and strength.'
Kidney disease increases the risk of muscle weakness with Lipitor.
No kidney disease risk factor statement is present in provided label excerpts (SECTION 2.5 states renal disease does not affect plasma concentrations or LDL-C reduction; no muscle risk linkage provided).
Liver disease increases the risk of muscle weakness with Lipitor.
Label excerpt states active liver disease is contraindicated (SECTION 4.1/8.6) and discusses liver enzyme abnormalities (SECTION 5.2) but does not state liver disease increases muscle weakness risk.
Taking other medications that can cause muscle weakness (e.g., antibiotics or antifungals) increases the risk of muscle weakness when taking Lipitor.
Label excerpt supports increased risk of myopathy with concurrent administration of certain drugs such as fibric acid derivatives, niacin, cyclosporine, and strong CYP3A4 inhibitors including clarithromycin, itraconazole (SECTION 5.1 and SECTION 7). It does not support the specific example grouping 'antibiotics or antifungals' in that way, nor the broader claim that other meds that 'can cause muscle weakness' generally increase risk.
If a person experiences muscle weakness while taking Lipitor, their doctor may recommend stopping Lipitor to see if the muscle weakness resolves.
No management instruction for muscle weakness (stop to see if resolves) is included in provided excerpts.
If a person experiences muscle weakness while taking Lipitor, their doctor may recommend switching to a different statin.
No label excerpt provided supports switching to a different statin as a specific recommendation for muscle weakness.
If a person experiences muscle weakness while taking Lipitor, their doctor may recommend monitoring muscle function to assess the severity of the muscle weakness.
No such monitoring recommendation for muscle function is included in provided excerpts.
It is not possible to completely prevent muscle weakness when taking Lipitor.
No such statement is present in provided label excerpts.
Following the recommended dosage of Lipitor may reduce the risk of muscle weakness.
Label excerpt does not make this causal/modifying statement about muscle weakness risk reduction via recommended dosage. It does discuss dose-related risk with higher doses/concomitant CYP3A4 inhibitors (SECTION 5.1) but not this generic 'recommended dosage reduces risk' wording.
Regularly monitoring muscle function may help reduce the risk of muscle weakness during Lipitor use.
No label excerpt provided supports this as a risk-reduction strategy.
Staying hydrated (drinking plenty of water) may help prevent muscle cramps during Lipitor use.
No hydration or prevention of muscle cramps guidance is included in the provided label excerpts.
Contradictions
Low
AI Statement
Kidney disease increases the risk of muscle weakness with Lipitor.
Label Reference
SECTION 2.5 — 'Renal disease does not affect the plasma concentrations nor LDL-C reduction of LIPITOR; thus, dosage adjustment… is not necessary.'
Important Omissions
Boxed warning, if any, is not discussed, and contraindications are not addressed (pregnancy, active liver disease, hypersensitivity, nursing).
Importance:
High
Dose and administration specifics (starting dose, dosing range, timing with/without food, and renal impairment statements) are not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims are either not supported by the provided label excerpts or provide overly specific guidance (incidence percentages, onset timing, hydration for prevention, and clinician actions for muscle weakness). The omission of contraindications/pregnancy and other key safety elements increases risk of incomplete or misleading safety understanding, though no direct contraindicated use instructions were provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Numerous specific safety/treatment/epidemiology claims (exact percentages, timing, risk factor details, and management and prevention advice) are not supported by the provided FDA label excerpts; contraindications and pregnancy/nursing warnings are omitted.
Suggested Improvement
Remove or rephrase unsupported specifics (incidence rates, onset timing, universal risk, hydration advice, and clinician management steps) and align statements strictly with the provided label sections: skeletal muscle risk (myopathy/rhabdomyolysis), advanced age caution (≥65), drug-interaction risk with strong CYP3A4 inhibitors (clarithromycin, itraconazole) and dose limits with cyclosporine, and include key contraindications (active liver disease, pregnancy, nursing).